Effects of a topical ointment on responses to treatments used for common genital diseases and on quality of life

Abstract Abstract   This study assessed the impacts of an ointment on treatment efficacy, side effects and global tolerance of most common genital diseases. This observational study enrolled symptomatic patients with LS and psoriasis under maintenance therapy (topical steroids); patients with condyloma acuminata treated with liquid nitrogen and/or imiquimod; patients suffering from vulvodynia under multidisciplinary treatment. The tested ointment was added to the usual treatment. Subjective and objective clinical scores, tolerance and Dermatology Life Quality Index (DLQI) were evaluated. One hundred patients completed the study: 26 LS, 6 psoriasis, 52 CA and 16 vulvodynia. There were significant reductions in global symptom and clinical scores for LS (−80.61% and −59.20%, respectively, mean follow-up 66 days) and psoriasis (−82.88% and −82.80%, respectively, mean follow-up of 51 days). The DLQI decreased by 40.17% for LS and 76.92% for psoriasis. The use of ointment resulted in low post-treatment scores for CA (Symptom score: 1.92/maximum 50, clinical score: 2.46/24 maximum, mean follow-up of 17 days). Tolerance was good for all except two patients (one CA, one vulvodynia). Our results indicated the daily applications of an ointment improved treatments for lichen sclerosus, psoriasis (symptoms, clinical signs and quality of life) and for condyloma acuminata (reduced healing time) and was well tolerated during vulvodynia.